Loading organizations...
§ Private Profile · Nanjing, Jiangsu, China
Clinical-stage biopharmaceutical company developing CAR-T cell therapies for cancer and autoimmune diseases.
IASO Biotherapeutics is a clinical-stage biopharmaceutical company specializing in cell therapies, particularly CAR-T treatments for cancer and autoimmune diseases, based in Nanjing, China, with operations in Pleasanton, California. The company develops both autologous and universal CAR-T products based on fully human antibody sequences, holding a portfolio of over 10 pipeline products. Its core approved product, Equecabtagene Autoleucel (eque-cel), is a CAR-T therapy approved in China for relapsed or refractory multiple myeloma. As of September 2021, IASO Bio had raised more than $178 million in equity financing, including a $108 million Series C round. Key investors include Hillhouse Capital (GL Ventures), CDH Baifu, CCB International, and Everbright Limited, supporting leadership such as CEO Wen (Maxwell) Wang and Co-founder Brian Hall. IASO Biotherapeutics was founded in March 2017 by Xuefei Huang.
IASO Biotherapeutics has raised $241.9M across 3 funding rounds.
IASO Biotherapeutics has raised $241.9M in total across 3 funding rounds.
IASO Biotherapeutics has raised $241.9M across 3 funding rounds. Most recently, it raised $73.9M Series C in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 18, 2023 | $73.9M Series C | — | Efung Capital, Hongcheng Investment, Housen Care Brothers, Nanjing Jiangbei NEW Area State Owned Asset Management, Shanghai Guoxin Investment & Development, Shanghai Waigaoqiao Free Trade Zone Group | Announced |
| Sep 16, 2021 | $108M Series C | WEI Ying | CCB International, China Everbright, Plaisance Capital Management | Announced |
| Mar 24, 2020 | $60M Series B | — | — | Announced |
IASO Biotherapeutics has raised $241.9M in total across 3 funding rounds.
IASO Biotherapeutics's investors include Efung Capital, Hongcheng Investment, Housen Care Brothers, Nanjing Jiangbei New Area State-owned Asset Management, Shanghai Guoxin Investment & Development, Shanghai Waigaoqiao Free Trade Zone Group, Wei Ying, CCB International, China Everbright, Plaisance Capital Management.